Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAME Extension Study
NCT01304706Phase 3Completed
- Sponsor
- Alimera Sciences
- Start
- Apr 2011
- Primary completion
- Nov 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluocinolone in diabetic macular edema (DME), sponsored by Alimera Sciences. Primary endpoint: Number of Participants With Adverse Events at 12 months. Started Apr 2011; status: completed.
02
Drugs
fluocinolone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01304706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01304706.